CLGN

Summary

CLGN (calmegin, HGNC:2060) is a protein-coding gene on chromosome 4q31.1, encoding Calmegin (O14967). Functions during spermatogenesis as a chaperone for a range of client proteins that are important for sperm adhesion onto the egg zona pellucida and for subsequent penetration of the zona pellucida.

Calmegin is a testis-specific endoplasmic reticulum chaperone protein. CLGN may play a role in spermatogeneisis and infertility.

Source: NCBI Gene 1047 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 104 total — 6 pathogenic, 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_004362

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2060
Approved symbol	CLGN
Name	calmegin
Location	4q31.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000153132
Ensembl biotype	protein_coding
OMIM	601858
Entrez	1047

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000325617, ENST00000414773, ENST00000509477, ENST00000897460, ENST00000931054, ENST00000931055, ENST00000963782, ENST00000963783, ENST00000963784, ENST00000963785

RefSeq mRNA: 2 — MANE Select: NM_004362 NM_001130675, NM_004362

CCDS: CCDS3751

Canonical transcript exons

ENST00000325617 — 15 exons

Exon	Start	End
ENSE00001008977	140392219	140392378
ENSE00001008979	140396092	140396205
ENSE00001008981	140398851	140399040
ENSE00001008982	140410553	140410626
ENSE00001008984	140400357	140400549
ENSE00001008985	140412935	140413087
ENSE00001008987	140392586	140392711
ENSE00001008988	140405942	140406083
ENSE00001008990	140395819	140395969
ENSE00001008991	140401985	140402066
ENSE00001008993	140409837	140409895
ENSE00001008994	140393826	140394041
ENSE00001008995	140390628	140390728
ENSE00002059656	140427537	140427648
ENSE00003843574	140388453	140389304

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 97.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.9418 / max 634.6791, expressed in 995 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
54122	7.6455	964
54121	1.0065	381
54124	0.2247	78
54123	0.0651	13

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart right ventricle	UBERON:0002080	97.25	gold quality
left ventricle myocardium	UBERON:0006566	95.59	gold quality
myocardium	UBERON:0002349	95.45	gold quality
left testis	UBERON:0004533	94.79	gold quality
right testis	UBERON:0004534	94.50	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.34	gold quality
testis	UBERON:0000473	93.03	gold quality
cardiac ventricle	UBERON:0002082	92.11	gold quality
heart left ventricle	UBERON:0002084	92.07	gold quality
cardiac atrium	UBERON:0002081	91.92	gold quality
right atrium auricular region	UBERON:0006631	91.74	gold quality
endothelial cell	CL:0000115	89.58	gold quality
islet of Langerhans	UBERON:0000006	89.17	gold quality
apex of heart	UBERON:0002098	88.20	gold quality
heart	UBERON:0000948	87.60	gold quality
pigmented layer of retina	UBERON:0001782	86.38	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.19	gold quality
ventricular zone	UBERON:0003053	83.34	gold quality
right uterine tube	UBERON:0001302	83.02	gold quality
pituitary gland	UBERON:0000007	82.36	gold quality
adenohypophysis	UBERON:0002196	82.06	gold quality
ganglionic eminence	UBERON:0004023	80.14	gold quality
choroid plexus epithelium	UBERON:0003911	79.59	gold quality
bronchial epithelial cell	CL:0002328	79.22	gold quality
prostate gland	UBERON:0002367	77.98	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.61	gold quality
cerebellar cortex	UBERON:0002129	77.60	gold quality
cerebellar hemisphere	UBERON:0002245	77.55	gold quality
embryo	UBERON:0000922	77.23	gold quality
adult organism	UBERON:0007023	76.40	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	25.16
E-MTAB-6058	no	390.67
E-ANND-3	no	3.31

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TCFL5

miRNA regulators (miRDB)

48 targeting CLGN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-409-3P	99.50	66.33	1192
HSA-MIR-12117	99.50	67.57	868
HSA-MIR-190B-3P	99.33	68.29	1382
HSA-MIR-1273H-3P	99.29	67.55	980
HSA-MIR-548AS-3P	99.12	69.12	2294
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-143-5P	98.98	68.87	946
HSA-MIR-3908	98.75	67.31	1160
HSA-MIR-11399	98.71	65.69	869
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-4766-3P	98.48	67.94	1347
HSA-MIR-6780A-3P	98.42	67.49	1518
HSA-MIR-654-3P	98.38	67.61	905

Literature-anchored findings (GeneRIF, showing 3)

• calmegin expression is regulated by histone deacetylase and CpG methyltransferase in a coordinative way (PMID:16264275)
• Although their similarity in carbohydrate binding specificities is high, there seems to be some differences in the mode of substrate recognition between calmegin and calnexin. (PMID:24769397)
• In gene-based analysis CLGN1 represented one of a cluster of genes, which interacted with sodium to influence Blood Pressure. (PMID:27271309)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	clgn	ENSDARG00000009315
mus_musculus	Clgn	ENSMUSG00000002190
rattus_norvegicus	Clgn	ENSRNOG00000003755
drosophila_melanogaster	Cnx99A	FBGN0015622
drosophila_melanogaster	CG1924	FBGN0030377
caenorhabditis_elegans		WBGENE00000567

Paralogs (3): CANX (ENSG00000127022), CALR (ENSG00000179218), CALR3 (ENSG00000269058)

Protein

Protein identifiers

Calmegin — O14967 (reviewed: O14967)

All UniProt accessions (3): O14967, A0A140VKG2, D6RAZ4

UniProt curated annotations — full annotation on UniProt →

Function. Functions during spermatogenesis as a chaperone for a range of client proteins that are important for sperm adhesion onto the egg zona pellucida and for subsequent penetration of the zona pellucida. Required for normal sperm migration from the uterus into the oviduct. Required for normal male fertility. Binds calcium ions.

Subunit / interactions. Interacts with PPIB. Interacts with ADAM2. Interacts with PDILT.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Detected in testis (at protein level). Detected in testis.

Similarity. Belongs to the calreticulin family.

Isoforms (2)

UniProt ID	Names	Canonical?
O14967-1	1	yes
O14967-2	2

RefSeq proteins (2): NP_001124147, NP_004353* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001580	Calret/calnex	Family
IPR009033	Calreticulin/calnexin_P_dom_sf	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR018124	Calret/calnex_CS	Conserved_site

Pfam: PF00262

UniProt features (37 total): repeat 8, modified residue 8, compositionally biased region 5, region of interest 3, sequence variant 3, topological domain 2, disulfide bond 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14967-F1	76.36	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 128, 560, 576, 579, 581, 591, 594, 601

Disulfide bonds (2): 151–185, 351–355

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 150 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, MODULE_169, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, PATIL_LIVER_CANCER, GOBP_PROTEIN_MATURATION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN, GOBP_SPERM_EGG_RECOGNITION, RIGGI_EWING_SARCOMA_PROGENITOR_DN, MODULE_99, GOBP_PROTEIN_FOLDING, SANSOM_APC_TARGETS_DN, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS

GO Biological Process (5): protein folding (GO:0006457), single fertilization (GO:0007338), binding of sperm to zona pellucida (GO:0007339), ERAD pathway (GO:0036503), protein-containing complex assembly (GO:0065003)

GO Molecular Function (4): calcium ion binding (GO:0005509), protein folding chaperone (GO:0044183), obsolete unfolded protein binding (GO:0051082), protein binding (GO:0005515)

GO Cellular Component (4): nuclear envelope (GO:0005635), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endomembrane system	2
cellular process	1
protein maturation	1
fertilization	1
sperm-egg recognition	1
proteasomal protein catabolic process	1
response to endoplasmic reticulum stress	1
response to chemical	1
cellular component assembly	1
protein-containing complex organization	1
metal ion binding	1
molecular_function	1
protein folding	1
binding	1
nucleus	1
organelle envelope	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1713 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLGN	ADAM2	P78326	962
CLGN	PDILT	Q8N807	659
CLGN	IZUMO1	Q8IYV9	559
CLGN	PPIB	P23284	548
CLGN	DEFB126	Q9BYW3	486
CLGN	TEX101	Q9BY14	485
CLGN	RNASE10	Q5GAN6	477
CLGN	UGGT1	Q9NYU2	475
CLGN	DCST2	Q5T1A1	472
CLGN	LY6K	Q17RY6	451
CLGN	TEKT3	Q9BXF9	447
CLGN	ENKUR	Q8TC29	443
CLGN	PRSS37	A4D1T9	436
CLGN	PDIA3	P30101	434
CLGN	PGAP1	Q75T13	411

IntAct

234 interactions, top by confidence:

A	B	Type	Score
TCTN2	CLGN	psi-mi:“MI:0914”(association)	0.780
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
B3GNT3	PGRMC1	psi-mi:“MI:0914”(association)	0.670
SLC12A2	CLGN	psi-mi:“MI:0914”(association)	0.640
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
INSR	PIK3R2	psi-mi:“MI:2364”(proximity)	0.570
SLC12A4	CLGN	psi-mi:“MI:0914”(association)	0.530
TOR1A	CLGN	psi-mi:“MI:0914”(association)	0.530
TOR1B	CLGN	psi-mi:“MI:0914”(association)	0.530
IGSF8	CLGN	psi-mi:“MI:0914”(association)	0.530
SMPD1	CLGN	psi-mi:“MI:0914”(association)	0.530
ATP6AP2	CLGN	psi-mi:“MI:0914”(association)	0.530
PIEZO1	CLGN	psi-mi:“MI:0914”(association)	0.530
POGLUT1	CLGN	psi-mi:“MI:0914”(association)	0.530
TMEM237	CLGN	psi-mi:“MI:0914”(association)	0.530
TMTC4	CLGN	psi-mi:“MI:0914”(association)	0.530
SCARB2	CLGN	psi-mi:“MI:0914”(association)	0.530
GPC3	CLGN	psi-mi:“MI:0914”(association)	0.530
SLC22A5	CLGN	psi-mi:“MI:0914”(association)	0.530
MBTPS1	CLGN	psi-mi:“MI:0914”(association)	0.530
GALNS	CLGN	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
OGFOD3	CLGN	psi-mi:“MI:0914”(association)	0.530
NCEH1	CLGN	psi-mi:“MI:0914”(association)	0.530

BioGRID (350): CLGN (Affinity Capture-MS), CLGN (Affinity Capture-MS), CLGN (Affinity Capture-MS), CLGN (Affinity Capture-MS), CLGN (Affinity Capture-MS), ABCC1 (Co-fractionation), CALU (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation), CLGN (Co-fractionation)

ESM2 similar proteins: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O18750, O81919, O82709, P08110, P11012, P14625, P24643, P27798, P27824, P29402, P29413, P34652, P35564, P35565, P36581, P41148, P52194, P83003, P93508, Q06814, Q23858, Q29092, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401, Q4R520, Q5R440, Q5R6F7

Diamond homologs: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O81919, O82709, P11012, P14211, P15253, P18418, P24643, P27797, P27798, P27824, P27825, P28491, P29402, P29413, P34652, P35564, P35565, P36581, P52193, P52194, P83003, P93508, Q06814, Q23858, Q2HWU3, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 221 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Glycosphingolipid metabolism	7	13.8×	1e-04
HS-GAG biosynthesis	5	11.3×	6e-03
Glycosaminoglycan metabolism	7	10.1×	6e-04
Sphingolipid metabolism	7	7.7×	3e-03
R-HSA-425393	9	7.6×	4e-04
Metabolism of carbohydrates and carbohydrate derivatives	9	7.1×	6e-04
SLC-mediated transmembrane transport	16	6.2×	4e-06
Transport of small molecules	21	3.5×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	1
Uncertain significance	84
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (7)

Variant ID	HGVS	Classification
1340411	GRCh37/hg19 4q28.3-31.21(chr4:136529470-141564812)x1	Pathogenic
3062804	GRCh37/hg19 4q27-35.2(chr4:123399154-190957473)x3	Pathogenic
3391884	GRCh37/hg19 4q28.3-31.21(chr4:137222514-142805472)x1	Pathogenic
3391885	GRCh37/hg19 4q28.3-31.21(chr4:137942896-145815498)x1	Pathogenic
4682609	GRCh37/hg19 4q28.3-31.21(chr4:134952803-144712496)x1	Pathogenic
814609	GRCh37/hg19 4q28.3-31.21(chr4:137901978-141527647)x1	Pathogenic
599571	NM_004362.3(CLGN):c.959A>G (p.Lys320Arg)	Likely pathogenic

SpliceAI

2482 predictions. Top by Δscore:

Variant	Effect	Δscore
4:140390649:A:AC	donor_gain	1.0000
4:140390650:T:C	donor_gain	1.0000
4:140390665:T:A	donor_gain	1.0000
4:140390726:CTT:C	acceptor_gain	1.0000
4:140390729:C:CC	acceptor_gain	1.0000
4:140390743:T:C	acceptor_gain	1.0000
4:140390743:T:TC	acceptor_gain	1.0000
4:140390746:T:C	acceptor_gain	1.0000
4:140390746:T:TC	acceptor_gain	1.0000
4:140392214:CTTAC:C	donor_loss	1.0000
4:140392215:TTAC:T	donor_loss	1.0000
4:140392217:A:T	donor_loss	1.0000
4:140392218:C:A	donor_loss	1.0000
4:140393890:T:TA	donor_gain	1.0000
4:140394040:CC:C	acceptor_gain	1.0000
4:140394041:CC:C	acceptor_gain	1.0000
4:140394042:C:CA	acceptor_loss	1.0000
4:140394043:T:G	acceptor_loss	1.0000
4:140395813:TGTTA:T	donor_loss	1.0000
4:140395814:GTTAC:G	donor_loss	1.0000
4:140395815:TTAC:T	donor_loss	1.0000
4:140395816:TA:T	donor_loss	1.0000
4:140395817:A:AT	donor_loss	1.0000
4:140395818:C:G	donor_loss	1.0000
4:140395965:CATTC:C	acceptor_gain	1.0000
4:140395967:TTC:T	acceptor_gain	1.0000
4:140395971:T:C	acceptor_gain	1.0000
4:140395971:T:TC	acceptor_gain	1.0000
4:140395976:A:AC	acceptor_gain	1.0000
4:140395976:A:C	acceptor_gain	1.0000

AlphaMissense

4098 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:140394035:A:G	W386R	0.993
4:140394035:A:T	W386R	0.993
4:140398901:C:A	W278C	0.991
4:140398901:C:G	W278C	0.991
4:140398903:A:G	W278R	0.991
4:140398903:A:T	W278R	0.991
4:140402015:T:A	K157N	0.991
4:140402015:T:G	K157N	0.991
4:140394033:C:A	W386C	0.990
4:140394033:C:G	W386C	0.990
4:140395854:A:G	W372R	0.990
4:140395854:A:T	W372R	0.990
4:140395894:C:A	W358C	0.990
4:140395894:C:G	W358C	0.990
4:140396150:A:G	W314R	0.990
4:140396150:A:T	W314R	0.990
4:140406078:A:G	W95R	0.990
4:140406078:A:T	W95R	0.990
4:140395916:C:G	C351S	0.989
4:140395917:A:T	C351S	0.989
4:140396148:C:A	W314C	0.989
4:140396148:C:G	W314C	0.989
4:140400359:A:G	L231P	0.989
4:140406000:C:G	A121P	0.989
4:140395896:A:G	W358R	0.988
4:140395896:A:T	W358R	0.988
4:140395904:C:G	C355S	0.988
4:140395905:A:T	C355S	0.988
4:140393947:A:G	L415P	0.987
4:140400511:A:C	F180L	0.987

dbSNP variants (sampled 300 via entrez): RS1000180732 (4:140413150 T>C), RS1000270046 (4:140405372 G>T), RS1000359321 (4:140424198 T>G), RS1000374276 (4:140423780 T>C), RS1000374823 (4:140413363 C>G,T), RS1000594790 (4:140392730 T>C), RS1000633192 (4:140408239 C>T), RS1000652122 (4:140425774 G>A), RS1000709153 (4:140406759 G>A), RS1000794498 (4:140395126 A>G), RS1000878125 (4:140425589 A>G), RS1000929731 (4:140419032 G>C), RS1001107324 (4:140401596 A>C), RS10011171 (4:140420114 C>A,T), RS10012138 (4:140421979 A>C,G)

Disease associations

OMIM: gene MIM:601858 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST000083_5	Select biomarker traits	1.000000e-06
GCST006111_1	Diastolic blood pressure x sodium interaction (2df test)	3.000000e-22
GCST006113_1	Systolic blood pressure x sodium interaction (2df test)	4.000000e-12
GCST006114_1	Mean arterial pressure x sodium interaction (2df test)	3.000000e-15
GCST010725_4	Malaria	4.000000e-10
GCST010725_84	Malaria	7.000000e-11
GCST010725_89	Malaria	7.000000e-11
GCST011742_48	Triglyceride levels in HIV infection	4.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004570	bilirubin measurement
EFO:0006336	diastolic blood pressure
EFO:0009282	sodium measurement
EFO:0006335	systolic blood pressure
EFO:0006340	mean arterial pressure
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295653 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

88 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
Cyclosporine	increases expression	4
bisphenol A	affects expression, increases expression	3
trichostatin A	affects cotreatment, decreases expression, increases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
perfluorooctane sulfonic acid	decreases expression, increases expression	2
(+)-JQ1 compound	increases expression	2
Vorinostat	decreases expression, increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	decreases expression	2
8-Bromo Cyclic Adenosine Monophosphate	increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
3,4-dichloroaniline	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
potassium chromate(VI)	increases expression	1
bicalutamide	increases expression	1
2,3-dimethoxy-1,4-naphthoquinone	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
entinostat	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118299	Binding	Inhibition of AurA in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled GKFGNVYLAR probe by mass-spectrometric analysis relative to control	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.